2-(2-tert-Butoxycarbonylaminoethylthio)-4-[(2-tert-butoxycarbonylaminoethyl)thiomethyl]-1,3-thiazole | 331779-49-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-(2-tert-Butoxycarbonylaminoethylthio)-4-[(2-tert-butoxycarbonylaminoethyl)thiomethyl]-1,3-thiazole
• 英文别名: tert-butyl N-[2-[[4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethylsulfanylmethyl]-1,3-thiazol-2-yl]sulfanyl]ethyl]carbamate
• CAS: 331779-49-8
• 化学式: C₁₈H₃₁N₃O₄S₃
• 分子量: 449.66
• InChiKey: AMNCGVLZUZXIIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  168
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-Bromo-4-[(2-tert-butoxycarbonylaminoethyl)thiomethyl]-1,3-thiazole 、 2-叔丁氧羰基氨基乙硫醇 以 叔丁醇 为溶剂， 生成 2-(2-tert-Butoxycarbonylaminoethylthio)-4-[(2-tert-butoxycarbonylaminoethyl)thiomethyl]-1,3-thiazole
  参考文献：
  名称：

  7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof

  摘要：

  本发明涉及具有III式或IV式的头孢菌素前药：或其药用可接受的盐，其中R′1选自由氢和—C(O)CH(NH2)CH3的群组，R′2选自由氢和在哺乳动物中发现的一种酶可水解的酰基团，但条件是当R′1或R′2中的一个是氢时，另一个不是。A、B、L、G、E和J分别独立地为氮或碳，使得相应的环被选自的群组选中，前提是群组—CH2—S—CH2CH2NHR′2仅连接到所述杂环基团的一个碳原子上，Q选自氮和—CX的群组，其中X选自氢和氯。

  公开号：

  US06723716B1

文献信息

• 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTICS AND PRODRUGS THEREOF
  申请人：Essential Therapeutics, Inc.

  公开号：EP1222194A1

  公开（公告）日：2002-07-17
• US6723716B1
  申请人：——

  公开号：US6723716B1

  公开（公告）日：2004-04-20
• [EN] 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIC ACID ANTIBIOTICS AND PRODRUGS THEREOF<br/>[FR] ANTIBIOTIQUES A L'ACIDE 7-ACYLAMINO-3-HETEROARYLTHIO-3-CEPHEM CARBOXYLIQUE ET PROMEDICAMENTS DE CES DERNIERS
  申请人：MICROCIDE PHARMACEUTICALS INC

  公开号：WO2001021623A1

  公开（公告）日：2001-03-29

  The present invention includes novel (7R)-7-acylamino-3-heteroarylthio-3-cephem-4-carboxylic acids or their pharmacologically acceptable salts and prodrugs thereof, which exhibit antibiotic activity against a wide spectrum of organisms including organisms which are resistant to β-lactam antibiotics and are useful as antibacterial agents. The invention also relates to novel intermediates useful for making the novel compounds of the present invention and to novel methods for producing the novel compounds and intermediate compounds.
• 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof
  申请人：Essential Therapeutics, Inc.

  公开号：US06723716B1

  公开（公告）日：2004-04-20

  The present invention relates to a cephem prodrug having formula III or formula IV: or a pharmaceutically acceptable salt thereof, wherein R′1 is selected from the group consisting of hydrogen and —C(O)CH(NH2)CH3 and R′2 is selected from the group consisting of hydrogen and an acyl group that is cleaved by an enzyme found in mammals, with the proviso that, when either R′1 or R′2 is hydrogen, the other is not. A, B, L, G, E, and J are each independently nitrogen or carbon such that the respective rings are selected from the group consisting of provided that the group —CH2—S—CH2CH2NHR′2 is attached only to a carbon atom of said heterocyclic group, and Q is selected from the group consisting of nitrogen and —CX, wherein X is selected from the group consisting of hydrogen and chlorine.

  本发明涉及具有III式或IV式的头孢菌素前药：或其药用可接受的盐，其中R′1选自由氢和—C(O)CH(NH2)CH3的群组，R′2选自由氢和在哺乳动物中发现的一种酶可水解的酰基团，但条件是当R′1或R′2中的一个是氢时，另一个不是。A、B、L、G、E和J分别独立地为氮或碳，使得相应的环被选自的群组选中，前提是群组—CH2—S—CH2CH2NHR′2仅连接到所述杂环基团的一个碳原子上，Q选自氮和—CX的群组，其中X选自氢和氯。